Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization.
Conclusions: Late afternoon administration of plerixafor provides efficient stem cell mobilization. PMID: 30186032 [PubMed]
ConclusionInguinal lymphocele that is not reabsorbed or does not resolve with conservative treatment should be surgically treated. Lymphocele excision with ligation of lymphatic vessels, followed by negative pressure wound therapy appears to be a safe and effective approach.
Authors: Sheng X, Tian C, Liu L, Wang L, Ye X, Li J, Zeng M, Liu L Abstract In the original publication the labelling of Figure 1D, Y-axis is incorrectly published. The correct labeling should be read as Fragilis+/SSEA1+ and the correct figure is provided in this correction. PMID: 31741146 [PubMed - as supplied by publisher]
This installment of what is in the literature is on amyotrophic lateral sclerosis (ALS). The pathophysiology of ALS remains open and the role of genes, a foothold into pathophysiology, but there are>22 genes identified, and the mechanisms are not known for any. Despite the lack of a firm understanding of pathophysiology, drug trials continue based on possible mechanisms, but no new drugs beyond riluzole and edaravone have been positive in phase 3 trials. There are a number of formal stem cell trials underway, and the results of a phase 2 trial are described. Major efforts to make trials more sensitive are being consider...
No abstract available
We certainly appreciate the thoughtful comments of Dr Lisotti and Dr Fusaroli1 on our article2 regarding the efficacy of contrast-enhanced EUS (CE-EUS) for differential diagnosis of lymphadenopathy. It should be emphasized, and as indicated in the article, we believe that the diagnostic capability of CE-EUS for lymphadenopathy is significantly improv ed by combining qualitative with quantitative analysis. In our study, because almost half of the malignant lymphoma showed a homogeneous enhancement pattern on CE-EUS, indicating a benign lesion, the assessment of lymphadenopathy using qualitative CE-EUS alone had limite...
Condition: Rheumatoid Arthritis Intervention: Biological: autologous adipose derived stem cells Sponsor: Celltex Therapeutics Corporation Not yet recruiting
Condition: Inflammatory Bowel Diseases Intervention: Procedure: Cord Blood Stem Cell Transplantation Sponsors: Children's Hospital of Fudan University; Shanghai Children's Hospital; Children's Hospital Of Soochow University; Beijing Children's Hospital; Guangzhou Women and Children's Medical Center; Shenzhen Children's Hospital; Wuhan Women and Children's Medical Center; Children’s Hospital...
Conditions: Relapsed and Refractory B Cell Lymphoma; Non-Hodgkin Lymphoma Intervention: Biological: CD20 CAR-T Sponsor: Shanghai Longyao Biotechnology Inc., Ltd. Recruiting
Conditions: Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma Interventions: Drug: Acalabrutinib; Biological: Obinutuzumab; Drug: Venetoclax Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting
ConclusionOverall, our results do not support an association between the WCRF/AICR score and CLL, yet we might have been limited by statistical power and study design to detect modest associations. Further research, ideally with a prospective design, long follow-up, and including additional lymphoma subtypes, is warranted to confirm the impact of composite healthy lifestyle behaviors on lymphoma risk.